Progenics Pharmaceuticals, Inc.

( )
PGNX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. -0.06%53.940.9%$1407.22m
JNJJohnson & Johnson -0.05%179.460.7%$1295.87m
BMYBristol-Myers Squibb Co. 0.00%77.591.0%$1212.16m
MRKMerck & Co., Inc. -0.01%92.310.7%$1166.90m
ABBVAbbVie, Inc. 0.20%150.861.9%$1102.49m
LLYEli Lilly & Co. -0.01%313.461.1%$967.22m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.14%142.980.0%$491.89m
AZNAstraZeneca Plc -0.11%66.631.0%$490.99m
NVSNovartis AG 0.00%91.260.2%$259.85m
GSKGlaxoSmithKline Plc 0.01%44.420.2%$257.59m
VERUVeru, Inc. 0.40%12.690.0%$254.71m
HZNPHorizon Therapeutics Plc 0.00%90.595.4%$196.03m
SGENSeagen Inc. 0.00%138.465.7%$185.67m
NVONovo Nordisk A/S -0.02%106.600.1%$182.86m
VTRSViatris, Inc. 0.00%12.010.0%$165.27m

Company Profile

Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.